Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 24263964)

1.

The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.

Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL.

Pharmacoeconomics. 2014 Jan;32(1):47-61. doi: 10.1007/s40273-013-0106-x.

PMID:
24263964
2.

Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.

Frederix GW, Severens JL, Hövels AM, Raaijmakers JA, Schellens JH.

Value Health. 2012 Jan;15(1):94-105. doi: 10.1016/j.jval.2011.08.003. Epub 2011 Oct 1. Review.

PMID:
22264977
3.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

5.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

6.
7.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.

Clin Breast Cancer. 2007 Jun;7(8):608-18.

PMID:
17592673
9.
10.
11.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

14.
15.
16.

A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.

John-Baptiste AA, Wu W, Rochon P, Anderson GM, Bell CM.

PLoS One. 2013 May 6;8(5):e62614. doi: 10.1371/journal.pone.0062614. Print 2013. Review.

18.

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A.

Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19.

PMID:
20389141
19.
20.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk